Knight Therapeutics Inc. (OTCMKTS:KHTRF) Short Interest Up 59.6% in March

Knight Therapeutics Inc. (OTCMKTS:KHTRFGet Rating) saw a large growth in short interest in March. As of March 31st, there was short interest totalling 300,100 shares, a growth of 59.6% from the March 15th total of 188,000 shares. Based on an average daily trading volume, of 200 shares, the short-interest ratio is presently 1,500.5 days.

KHTRF stock remained flat at $$4.20 during mid-day trading on Friday. The company’s fifty day moving average price is $4.24 and its two-hundred day moving average price is $4.21. Knight Therapeutics has a 12 month low of $3.66 and a 12 month high of $4.64.

A number of research analysts have recently weighed in on the company. Knight Equity cut their price objective on Knight Therapeutics from C$8.00 to C$7.00 in a report on Friday, March 25th. Stifel Nicolaus lowered Knight Therapeutics from a “buy” rating to a “hold” rating and cut their price objective for the company from C$7.00 to C$5.30 in a report on Friday, March 25th. Finally, Raymond James cut their price objective on Knight Therapeutics from C$8.50 to C$7.50 in a report on Friday, March 25th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from, the company has an average rating of “Buy” and a consensus target price of $6.81.

About Knight Therapeutics (Get Rating)

Knight Therapeutics Inc, a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada and internationally. It offers Bijuva for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with intact uterus; IMVEXXY to treat postmenopausal moderate to severe dyspareunia; IBSRELA for the treatment of irritable bowel syndrome with constipation in adults; TRELSTAR to treat advanced prostate cancer and for pain associated with endometriosis; ILUVIEN for the treatment of vision loss due to diabetic macular oedema; and NERLYNX to treat early-stage breast cancer.

Read More

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with's FREE daily email newsletter.